key: cord-0915853-5jv86ai4
authors: El-Sayed, Naglaa Salem; Jureka, Alexander S.; Edwards, Megan R.; Lohan, Sandeep; Williams, Caroline G.; Keiser, Patrick T.; Davey, Robert A.; Totonchy, Jennifer; Tiwari, Rakesh K.; Basler, Christopher F.; Parang, Keykavous
title: Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus
date: 2021-09-21
journal: Eur J Med Chem
DOI: 10.1016/j.ejmech.2021.113862
sha: c0122400a0de9800d461de964a6bc6e4127ee697
doc_id: 915853
cord_uid: 5jv86ai4

We report here the synthesis, purification, and characterization of mono- and di-fatty acyl conjugates of remdesivir (RDV) and their in vitro antiviral activity against SAR-CoV-2, an Ebola virus transcription- and replication-competent virus-like particle (trVLP) system, and infectious Ebola virus. The most potent monofatty acyl conjugate was 4b, containing a 4-oxatetradecanolyl at the 3′ position. Monofatty acyl conjugates, 3′-O-tetradecanoyl (4a) (IC50(VeroE6) = 2.3 μM; IC50(Calu3) = 0.24 μM), 3′-O-4-oxatetradodecanoyl (4b) (IC50(VeroE6) = 2.0 μM; IC50(Calu3) = 0.18 μM), and 3′-O-(12-ethylthiododecanoyl) (4e) (IC50(VeroE6) = 2.4 μM; IC50(Calu3) = 0.25 μM) derivatives exhibited less activity than RDV (IC50(VeroE6) = 0.85 μM; IC50(Calu3) = 0.06 μM) in both VeroE6 and Calu3 cells. Difatty acylation led to a significant reduction in the antiviral activity of RDV (as shown in conjugates 5a and 5b) against SARS-CoV-2 when compared with monofatty acylation (3a-e and 4a-e). About 77.9% of 4c remained intact after 4 h incubation with human plasma while only 47% of parent RDV was observed at the 2 h time point. The results clearly indicate the effectiveness of fatty acylation to improve the half-life of RDV. The antiviral activities of a number of monofatty acyl conjugates of RDV, such as 3b, 3e, and 4b, were comparable with RDV against the Ebola trVLP system. Meanwhile, the corresponding physical mixtures of RDV and fatty acids 6a and 6b showed 1.6 to 2.2 times less antiviral activity than the corresponding conjugates, 4a and 4c, respectively, against SARS-CoV-2 in VeroE6 cells. A significant reduction in viral RNA synthesis was observed for selected compounds 3a and 4b consistent with the IC50 results. These studies indicate the potential of these compounds as long-acting antiviral agents or prodrugs of RDV.

In the second step, fatty acylation was performed by reacting an equimolar amount of the 206 corresponding fatty acyl chloride with a dilute solution of RDV (1) in the presence of 207 diisopropylethylamine (DIPEA) for 5-9 h to generate monofatty acyl derivatives that correspond 208 to 2′-and 3´-fatty acyl RDV conjugates as 3a-e and 4a-e, respectively. The free aromatic amine of 209 remdesivir has been shown to be less reactive than free 2′ and 3′-hydroxy groups [2,3]. The 210 corresponding compounds from both series have the same molecular weight but differ in their 211 chemical structures. Meanwhile, the use of 3 molar equivalents of fatty acyl chloride and 1 molar 212 equivalent of RDV (1) yielded the 2´,3´-difatty acyl derivatives of RDV (5a and 5b) (Scheme 1). 213 Employing this conjugation plan by controlling the coupling conditions (i.e. reactant e) and reduced the number of reaction steps, time, and solvents required for purification. This is in 217 contrast to the protection and deprotection strategies, which involve the selective protection of 218 different functional groups with proper protecting agents, purification of the protected 219 intermediates, coupling with a fatty acyl chloride, purification, removal of the protecting group, 220 and purification of the final products in reduced yield.

Mono 3′-fatty acyl derivatives 4a-e were obtained in higher yield as compared to 2′-fatty 222 acyl derivatives 3a-e, possibly due to the higher reactivity of the 3´-hydroxyl group than the 2´-223 hydroxyl group of RDV. The presence of an adjacent strong electron-withdrawing group (CN) at 224 C-1′ in RDV reduces the nucleophilicity of the 2′-hydroxyl group; therefore, the carboxy chloride 225 of the fatty acid tends to react more efficiently with the 3´-hydroxy group. The two fatty acyl 226 monoconjugates were separated on semi-preparative reverse-phase high-performance liquid 227 chromatography (RP-HPLC) and fully characterized using nuclear magnetic resonance (NMR) 228 and mass spectroscopy (Supporting Information; See methods).

The attachment of the long-chain fatty acid analogs to RDV enhanced their lipophilicity, 230 as shown by calculated partition coefficients (CLog P) (Table 1) . Difatty acyl conjugates (5a and 231 5b) exhibited significantly higher lipophilicity due to a large number of methylene chains as 232 compared with a smaller number of methylene chains in monofatty acyl conjugates 3a-e and 4a-e 233 (Table 1) . Monopalmitoyl conjugates 3e and 4e were more lipophilic than monofatty acyl 234 conjugates with shorter chain lengths, such as tetradecanoyl derivatives 3a and 4a. The higher Table 2 . that upon cellular delivery and hydrolysis to RDV, the long-acting effect of RDV is to be observed.

These conjugates were designed as prodrugs to improve the physicochemical properties of RDV 324 to be used in oral administration or as long-acting antiviral agents. Further investigation is required 325 to determine the prodrug properties and long-acting activity of the conjugates. 362 To analyze the stability imparted by fatty acylation of the parent compound, we determined 

Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric

Expressing the SARS-CoV-2 RNA Polymerase in Mice

GS-5734) is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

Remdesivir: Review of Pharmacology, Pre-869 clinical Data, and Emerging Clinical Experience for COVID-19

Remdesivir is a Direct-Acting Antiviral that Inhibits RNA-Dependent RNA Polymerase 873 from Severe Acute Respiratory Syndrome Coronavirus 2 with High Potency

Vitro Anti-Hepatitis B 876 Virus Activities of 5′-O-Myristoyl Analogue Derivatives of 3-Fluoro-2′

Dideoxythymidine (FLT) and 3′-Azido-2′,3′-Dideoxythymidine (AZT)

Synthesis and Anti-HIV Activities of Phosphate 880

Triester Derivatives of 3′-Fluoro-2′,3′-Dideoxythymidine and 3′-Azido-2′

Synthesis and 895 Characterization of a Long-Acting Emtricitabine Prodrug Nanoformulation

A Long-Acting 3TC ProTide

Nanoformulation Suppresses HBV Replication in Humanized Mice

Sustained Intracellular Raltegravir Depots Generated with Prodrugs 904

Designed for Nanoparticle Delivery

Tenofovir alafenamide: A Novel Prodrug of

Tenofovir for the Treatment of Human Immunodeficiency Virus

Improving Maraviroc Oral Bioavailability by Formation of Solid Drug

Assessment of 914 Interactions of Efavirenz Solid Drug Nanoparticles with Human Immunological

Rethinking Remdesivir: Synthesis of Lipid Prodrugs 919 that Substantially Enhance Anti-Coronavirus Activity

Structural Basis for Inhibition of the RNA-Dependent 924

RNA Polymerase from SARS-CoV-2 by Remdesivir

Inhibitors of VPS34 927 and Lipid Metabolism Suppress SARS-CoV-2 Replication

A Novel Life Cycle Modeling System for Ebola Virus Shows a 931

Genome Length-Dependent Role of VP24 in Virus Infectivity

Propagation, Inactivation, and Safety Testing of 934 SARS-CoV-2